Sanctuary Advisors LLC Takes $647,000 Position in Qiagen (NYSE:QGEN)

Sanctuary Advisors LLC bought a new stake in shares of Qiagen (NYSE:QGEN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 15,628 shares of the company’s stock, valued at approximately $647,000.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Qiagen by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 8,815,467 shares of the company’s stock worth $382,856,000 after buying an additional 83,371 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Qiagen by 124.4% during the 1st quarter. US Bancorp DE now owns 75,529 shares of the company’s stock valued at $3,247,000 after purchasing an additional 41,868 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Qiagen by 25.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,689,763 shares of the company’s stock valued at $72,643,000 after purchasing an additional 344,275 shares in the last quarter. TD Asset Management Inc purchased a new position in shares of Qiagen during the second quarter valued at about $2,103,000. Finally, Edgestream Partners L.P. bought a new stake in shares of Qiagen in the first quarter worth about $1,492,000. Institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Wolfe Research raised Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a research note on Thursday, June 27th. JPMorgan Chase & Co. boosted their price target on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Finally, Robert W. Baird increased their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.25.

Qiagen Price Performance

QGEN stock opened at $44.09 on Tuesday. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27. Qiagen has a 12 month low of $34.74 and a 12 month high of $47.44. The stock has a market cap of $10.06 billion, a PE ratio of 29.59, a P/E/G ratio of 3.39 and a beta of 0.39. The company has a 50-day moving average price of $45.24 and a 200 day moving average price of $43.52.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The firm had revenue of $496.00 million for the quarter, compared to analysts’ expectations of $495.45 million. During the same quarter in the prior year, the firm posted $0.53 earnings per share. The company’s quarterly revenue was down .2% on a year-over-year basis. Equities research analysts anticipate that Qiagen will post 2.15 earnings per share for the current year.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.